JASON EHRLICH - 15 Jun 2022 Form 4 Insider Report for Kodiak Sciences Inc. (KOD)

Role
Chief Medical Officer and Chief Development Officer
Signature
/s/ David Peinsipp, Attorney-in-Fact for Jason Ehrlich
Issuer symbol
KOD
Transactions as of
15 Jun 2022
Net transactions value
-$24,708
Form type
4
Filing time
17 Jun 2022, 19:56:02 UTC
Previous filing
14 Jun 2022
Next filing
08 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KOD Common Stock Options Exercise +5,494 +10% 60,407 15 Jun 2022 Direct F1
transaction KOD Common Stock Sale $8,688 -1,205 -2% $7.21 59,202 15 Jun 2022 Direct F2
transaction KOD Common Stock Sale $16,020 -2,282 -3.9% $7.02 56,920 17 Jun 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KOD Restricted Stock Units Options Exercise $0 -3,619 -33% $0.000000 7,238 15 Jun 2022 Common Stock 3,619 Direct F1, F4
transaction KOD Restricted Stock Units Options Exercise $0 -1,875 -25% $0.000000 5,625 15 Jun 2022 Common Stock 1,875 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.
F2 The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the RSUs on June 11, 2022. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F3 The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the RSUs on June 15, 2022. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F4 One-fourth (1/4th) of the RSUs vest on each of the first four anniversaries of June 15, 2020, subject to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.
F5 One-fourth (1/4th) of the RSUs vest on each of the first four anniversaries of June 15, 2021, subject to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.

Remarks:

Chief Medical Officer and Chief Development Officer